Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-08-16

AUTHORS

Alexander Stein, Gabriel Glockzin, Andreas Wienke, Dirk Arnold, Thomas Edelmann, Bert Hildebrandt, Stephan Hollerbach, Gerald Illerhaus, Alfred Königsrainer, Michael Richter, Hans J Schlitt, Hans-Joachim Schmoll

ABSTRACT

BACKGROUND: More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis. METHODS/DESIGN: In these two multi-centre, randomized phase II trials, conducted in Germany, 380 patients with R0-resectable colorectal liver metastases (PERIMAX) and with unresectable, metastatic colorectal cancer (CHARTA) will be recruited. Patients previously untreated for metastatic disease with either synchronous or metachronous metastases are randomly assigned in a 1:1 ratio to resection of colorectal liver metastases followed by postoperative FOLFOX for 6 months or perioperative FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and resection (PERIMAX), or to induction chemotherapy with FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab. The primary objective of these trials is to evaluate the feasibility and efficacy of FOLFOXIRI and bevacizumab in metastatic colorectal cancer. Primary endpoint is failure free survival rate at 18 months in the PERIMAX trial and progression free survival rate at 9 months in CHARTA. Secondary objectives include efficacy, safety and tolerability. DISCUSSION: The CHARTA and PERIMAX trials are designed to evaluate the benefits and limitations of a highly active four-drug regimen in distinct treatment situations of metastatic CRC. Eligible patients are classified into resectable liver metastases to be randomized to perioperative treatment with FOLFOXIRI and bevacizumab or postoperative FOLFOX in the PERIMAX, or unresectable metastatic CRC to be randomized between FOLFOX and bevacizumab with or without irinotecan, stratified for clinical groups according to disease and patients' characteristics in the CHARTA trial. TRIAL REGISTRATION: Clinical trial identifier CHARTA: NCT01321957, PERIMAX: NCT01540435. More... »

PAGES

356-356

References to SciGraph publications

  • 2010-10-19. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial in BRITISH JOURNAL OF CANCER
  • 2007-09-28. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2010-10-11. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment in BMC CANCER
  • 1995-01. Resection of colorectal liver metastases in WORLD JOURNAL OF SURGERY
  • 2006-02-28. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) in BRITISH JOURNAL OF CANCER
  • 2007-01-31. Extended Resections of Liver Metastases from Colorectal Cancer in WORLD JOURNAL OF SURGERY
  • 2010-10-19. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study in BMC CANCER
  • 2010-03-09. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis in BRITISH JOURNAL OF CANCER
  • 2006-03-10. Survival After Hepatic Resection for Colorectal Metastases: A 10-Year Experience in ANNALS OF SURGICAL ONCOLOGY
  • Journal

    TITLE

    BMC Cancer

    ISSUE

    1

    VOLUME

    12

    Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/1471-2407-12-356

    DOI

    http://dx.doi.org/10.1186/1471-2407-12-356

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1032414305

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/22897915


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bevacizumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Camptothecin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Colorectal Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Combined Modality Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease-Free Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fluorouracil", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Irinotecan", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leucovorin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Multicenter Studies as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organoplatinum Compounds", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Randomized Controlled Trials as Topic", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.412315.0", 
              "name": [
                "University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stein", 
            "givenName": "Alexander", 
            "id": "sg:person.01121153617.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121153617.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Surgery, University Medical Center Regensburg, Regensburg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411941.8", 
              "name": [
                "Department of Surgery, University Medical Center Regensburg, Regensburg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Glockzin", 
            "givenName": "Gabriel", 
            "id": "sg:person.01370366160.73", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370366160.73"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department for Oncology/Hematology, Martin-Luther-University Halle, Ernst-Grube-Str. 40, 06120, Halle/Saale, Germany", 
              "id": "http://www.grid.ac/institutes/grid.9018.0", 
              "name": [
                "Department for Oncology/Hematology, Martin-Luther-University Halle, Ernst-Grube-Str. 40, 06120, Halle/Saale, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wienke", 
            "givenName": "Andreas", 
            "id": "sg:person.0725537546.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725537546.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.412315.0", 
              "name": [
                "University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Arnold", 
            "givenName": "Dirk", 
            "id": "sg:person.01270303133.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270303133.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MedCenter Nordsachsen, Schkeuditz, Germany", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "MedCenter Nordsachsen, Schkeuditz, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Edelmann", 
            "givenName": "Thomas", 
            "id": "sg:person.015465611257.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015465611257.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Charit\u00e9 Centrum f\u00fcr Tumormedizin, Campus Virchow-Klinikum, Berlin, Germany", 
              "id": "http://www.grid.ac/institutes/grid.6363.0", 
              "name": [
                "Charit\u00e9 Centrum f\u00fcr Tumormedizin, Campus Virchow-Klinikum, Berlin, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hildebrandt", 
            "givenName": "Bert", 
            "id": "sg:person.0620147214.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620147214.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department for Gastroenterology, Academic Teaching Hospital, Celle, Germany", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department for Gastroenterology, Academic Teaching Hospital, Celle, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hollerbach", 
            "givenName": "Stephan", 
            "id": "sg:person.015247652534.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015247652534.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology/Oncology, Comprehensive Cancer Center University of Freiburg, Freiburg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.5963.9", 
              "name": [
                "Department of Hematology/Oncology, Comprehensive Cancer Center University of Freiburg, Freiburg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Illerhaus", 
            "givenName": "Gerald", 
            "id": "sg:person.0771113555.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771113555.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Surgery, University Hospital of T\u00fcbingen, T\u00fcbingen, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411544.1", 
              "name": [
                "Department of Surgery, University Hospital of T\u00fcbingen, T\u00fcbingen, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "K\u00f6nigsrainer", 
            "givenName": "Alfred", 
            "id": "sg:person.01237306027.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237306027.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Koordinierungszentrum Klinische Studien Halle, Martin-Luther-University, Halle, Germany", 
              "id": "http://www.grid.ac/institutes/grid.9018.0", 
              "name": [
                "Koordinierungszentrum Klinische Studien Halle, Martin-Luther-University, Halle, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Richter", 
            "givenName": "Michael", 
            "id": "sg:person.01044006441.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044006441.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Surgery, University Medical Center Regensburg, Regensburg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.411941.8", 
              "name": [
                "Department of Surgery, University Medical Center Regensburg, Regensburg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schlitt", 
            "givenName": "Hans J", 
            "id": "sg:person.010361144542.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010361144542.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department for Oncology/Hematology, Martin-Luther-University Halle, Ernst-Grube-Str. 40, 06120, Halle/Saale, Germany", 
              "id": "http://www.grid.ac/institutes/grid.9018.0", 
              "name": [
                "Department for Oncology/Hematology, Martin-Luther-University Halle, Ernst-Grube-Str. 40, 06120, Halle/Saale, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schmoll", 
            "givenName": "Hans-Joachim", 
            "id": "sg:person.0665375546.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665375546.55"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.bjc.6605940", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008545199", 
              "https://doi.org/10.1038/sj.bjc.6605940"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6603011", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024247066", 
              "https://doi.org/10.1038/sj.bjc.6603011"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-007-0588-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029987674", 
              "https://doi.org/10.1007/s00280-007-0588-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00316981", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038122014", 
              "https://doi.org/10.1007/bf00316981"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/aso.2006.05.039", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035845557", 
              "https://doi.org/10.1245/aso.2006.05.039"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2407-10-545", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021313491", 
              "https://doi.org/10.1186/1471-2407-10-545"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6605595", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007402265", 
              "https://doi.org/10.1038/sj.bjc.6605595"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00268-006-0140-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003334308", 
              "https://doi.org/10.1007/s00268-006-0140-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2407-10-567", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017854165", 
              "https://doi.org/10.1186/1471-2407-10-567"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2012-08-16", 
        "datePublishedReg": "2012-08-16", 
        "description": "BACKGROUND: More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis.\nMETHODS/DESIGN: In these two multi-centre, randomized phase II trials, conducted in Germany, 380 patients with R0-resectable colorectal liver metastases (PERIMAX) and with unresectable, metastatic colorectal cancer (CHARTA) will be recruited. Patients previously untreated for metastatic disease with either synchronous or metachronous metastases are randomly assigned in a 1:1 ratio to resection of colorectal liver metastases followed by postoperative FOLFOX for 6 months or perioperative FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and resection (PERIMAX), or to induction chemotherapy with FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab. The primary objective of these trials is to evaluate the feasibility and efficacy of FOLFOXIRI and bevacizumab in metastatic colorectal cancer. Primary endpoint is failure free survival rate at 18 months in the PERIMAX trial and progression free survival rate at 9 months in CHARTA. Secondary objectives include efficacy, safety and tolerability.\nDISCUSSION: The CHARTA and PERIMAX trials are designed to evaluate the benefits and limitations of a highly active four-drug regimen in distinct treatment situations of metastatic CRC. Eligible patients are classified into resectable liver metastases to be randomized to perioperative treatment with FOLFOXIRI and bevacizumab or postoperative FOLFOX in the PERIMAX, or unresectable metastatic CRC to be randomized between FOLFOX and bevacizumab with or without irinotecan, stratified for clinical groups according to disease and patients' characteristics in the CHARTA trial.\nTRIAL REGISTRATION: Clinical trial identifier CHARTA: NCT01321957, PERIMAX: NCT01540435.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/1471-2407-12-356", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1024632", 
            "issn": [
              "1471-2407"
            ], 
            "name": "BMC Cancer", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "12"
          }
        ], 
        "keywords": [
          "colorectal liver metastases", 
          "metastatic colorectal cancer", 
          "free survival rate", 
          "colorectal cancer", 
          "liver metastases", 
          "metastatic disease", 
          "metastatic CRC", 
          "survival rate", 
          "progression-free survival rates", 
          "randomized phase II trial", 
          "failure-free survival rate", 
          "further treatment intensification", 
          "efficacy of FOLFOXIRI", 
          "resectable liver metastases", 
          "four-drug regimen", 
          "half of patients", 
          "phase II trial", 
          "advanced colorectal cancer", 
          "course of disease", 
          "treatment intensification", 
          "eligible patients", 
          "perioperative treatment", 
          "II trial", 
          "primary endpoint", 
          "metachronous metastases", 
          "patient characteristics", 
          "limited prognosis", 
          "initial diagnosis", 
          "maintenance treatment", 
          "bevacizumab", 
          "FOLFOX", 
          "FOLFOXIRI", 
          "patients", 
          "metastasis", 
          "secondary objective", 
          "clinical groups", 
          "cancer", 
          "disease", 
          "trials", 
          "months", 
          "novel trial", 
          "resection", 
          "treatment situation", 
          "treatment", 
          "CRC", 
          "efficacy", 
          "primary objective", 
          "tolerability", 
          "fluoropyrimidines", 
          "regimen", 
          "chemotherapy", 
          "prognosis", 
          "irinotecan", 
          "diagnosis", 
          "endpoint", 
          "presentation", 
          "rate", 
          "safety", 
          "review", 
          "group", 
          "objective", 
          "course", 
          "half", 
          "benefits", 
          "characteristics", 
          "literature", 
          "feasibility", 
          "ratio", 
          "time", 
          "limitations", 
          "Germany", 
          "situation", 
          "maximum", 
          "Charta", 
          "intensification", 
          "multidisciplinary management further treatment intensification", 
          "management further treatment intensification", 
          "R0-resectable colorectal liver metastases", 
          "postoperative FOLFOX", 
          "perioperative FOLFOXIRI", 
          "PERIMAX trial", 
          "distinct treatment situations", 
          "PERIMAX", 
          "unresectable metastatic CRC", 
          "CHARTA trial", 
          "Clinical trial identifier CHARTA", 
          "trial identifier CHARTA", 
          "identifier CHARTA", 
          "NCT01321957", 
          "NCT01540435"
        ], 
        "name": "Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature", 
        "pagination": "356-356", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1032414305"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/1471-2407-12-356"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "22897915"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/1471-2407-12-356", 
          "https://app.dimensions.ai/details/publication/pub.1032414305"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:26", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_558.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/1471-2407-12-356"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-356'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-356'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-356'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-356'


     

    This table displays all metadata directly associated to this object as RDF triples.

    346 TRIPLES      22 PREDICATES      140 URIs      123 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/1471-2407-12-356 schema:about N00f41bb8124a4a93aa740db44def8120
    2 N193e9fa7e627451fbdca3d1805dbe136
    3 N21585e032df44a8cb8b98390298c9dc6
    4 N260b158288a34a01bd60909bd3fe691d
    5 N26ec781f5c6045a2b72c666ba0a60795
    6 N37bc006acc11401a82f093e4c2595b51
    7 N483d23c304a24abb9b30eea3b890453a
    8 N49ed195f15a44c009e2e03b0d6497719
    9 N6d0d9c9783eb4517baec9c4e4471ba53
    10 N835b9b3b5ce348a4b02180fdc3c301a6
    11 Nc11b3c3ba76f420c886e2eeafe03fd41
    12 Ncdaa7f8034984bbf87bc47e12d3ffbfa
    13 Ncf33fb70b7eb4512a37089448c8c5a21
    14 Nf44d450238fd4479be67204294e98a54
    15 Nfa76187e05054c4f9a182c26a44ab61c
    16 anzsrc-for:11
    17 anzsrc-for:1112
    18 schema:author N605e25359dae438496f939db88e81a9f
    19 schema:citation sg:pub.10.1007/bf00316981
    20 sg:pub.10.1007/s00268-006-0140-3
    21 sg:pub.10.1007/s00280-007-0588-3
    22 sg:pub.10.1038/sj.bjc.6603011
    23 sg:pub.10.1038/sj.bjc.6605595
    24 sg:pub.10.1038/sj.bjc.6605940
    25 sg:pub.10.1186/1471-2407-10-545
    26 sg:pub.10.1186/1471-2407-10-567
    27 sg:pub.10.1245/aso.2006.05.039
    28 schema:datePublished 2012-08-16
    29 schema:datePublishedReg 2012-08-16
    30 schema:description BACKGROUND: More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis. METHODS/DESIGN: In these two multi-centre, randomized phase II trials, conducted in Germany, 380 patients with R0-resectable colorectal liver metastases (PERIMAX) and with unresectable, metastatic colorectal cancer (CHARTA) will be recruited. Patients previously untreated for metastatic disease with either synchronous or metachronous metastases are randomly assigned in a 1:1 ratio to resection of colorectal liver metastases followed by postoperative FOLFOX for 6 months or perioperative FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and resection (PERIMAX), or to induction chemotherapy with FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab. The primary objective of these trials is to evaluate the feasibility and efficacy of FOLFOXIRI and bevacizumab in metastatic colorectal cancer. Primary endpoint is failure free survival rate at 18 months in the PERIMAX trial and progression free survival rate at 9 months in CHARTA. Secondary objectives include efficacy, safety and tolerability. DISCUSSION: The CHARTA and PERIMAX trials are designed to evaluate the benefits and limitations of a highly active four-drug regimen in distinct treatment situations of metastatic CRC. Eligible patients are classified into resectable liver metastases to be randomized to perioperative treatment with FOLFOXIRI and bevacizumab or postoperative FOLFOX in the PERIMAX, or unresectable metastatic CRC to be randomized between FOLFOX and bevacizumab with or without irinotecan, stratified for clinical groups according to disease and patients' characteristics in the CHARTA trial. TRIAL REGISTRATION: Clinical trial identifier CHARTA: NCT01321957, PERIMAX: NCT01540435.
    31 schema:genre article
    32 schema:inLanguage en
    33 schema:isAccessibleForFree true
    34 schema:isPartOf N8976e451fbec4aae897a08ca1cf78b34
    35 N92f48c3248e84d968f0d27085d478000
    36 sg:journal.1024632
    37 schema:keywords CHARTA trial
    38 CRC
    39 Charta
    40 Clinical trial identifier CHARTA
    41 FOLFOX
    42 FOLFOXIRI
    43 Germany
    44 II trial
    45 NCT01321957
    46 NCT01540435
    47 PERIMAX
    48 PERIMAX trial
    49 R0-resectable colorectal liver metastases
    50 advanced colorectal cancer
    51 benefits
    52 bevacizumab
    53 cancer
    54 characteristics
    55 chemotherapy
    56 clinical groups
    57 colorectal cancer
    58 colorectal liver metastases
    59 course
    60 course of disease
    61 diagnosis
    62 disease
    63 distinct treatment situations
    64 efficacy
    65 efficacy of FOLFOXIRI
    66 eligible patients
    67 endpoint
    68 failure-free survival rate
    69 feasibility
    70 fluoropyrimidines
    71 four-drug regimen
    72 free survival rate
    73 further treatment intensification
    74 group
    75 half
    76 half of patients
    77 identifier CHARTA
    78 initial diagnosis
    79 intensification
    80 irinotecan
    81 limitations
    82 limited prognosis
    83 literature
    84 liver metastases
    85 maintenance treatment
    86 management further treatment intensification
    87 maximum
    88 metachronous metastases
    89 metastasis
    90 metastatic CRC
    91 metastatic colorectal cancer
    92 metastatic disease
    93 months
    94 multidisciplinary management further treatment intensification
    95 novel trial
    96 objective
    97 patient characteristics
    98 patients
    99 perioperative FOLFOXIRI
    100 perioperative treatment
    101 phase II trial
    102 postoperative FOLFOX
    103 presentation
    104 primary endpoint
    105 primary objective
    106 prognosis
    107 progression-free survival rates
    108 randomized phase II trial
    109 rate
    110 ratio
    111 regimen
    112 resectable liver metastases
    113 resection
    114 review
    115 safety
    116 secondary objective
    117 situation
    118 survival rate
    119 time
    120 tolerability
    121 treatment
    122 treatment intensification
    123 treatment situation
    124 trial identifier CHARTA
    125 trials
    126 unresectable metastatic CRC
    127 schema:name Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
    128 schema:pagination 356-356
    129 schema:productId N474bc2bd6bd9409f918322e4acc1be11
    130 N82ee13284dd340d1b5419f82e955a049
    131 Nc2ba760a224b40349f2f9da6b8267b4c
    132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032414305
    133 https://doi.org/10.1186/1471-2407-12-356
    134 schema:sdDatePublished 2021-12-01T19:26
    135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    136 schema:sdPublisher N3361a6cd9c354432832be4fa86752068
    137 schema:url https://doi.org/10.1186/1471-2407-12-356
    138 sgo:license sg:explorer/license/
    139 sgo:sdDataset articles
    140 rdf:type schema:ScholarlyArticle
    141 N00f41bb8124a4a93aa740db44def8120 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Disease-Free Survival
    143 rdf:type schema:DefinedTerm
    144 N193e9fa7e627451fbdca3d1805dbe136 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Humans
    146 rdf:type schema:DefinedTerm
    147 N21585e032df44a8cb8b98390298c9dc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Leucovorin
    149 rdf:type schema:DefinedTerm
    150 N240d23d438c24bc789a00f547e475782 rdf:first sg:person.01370366160.73
    151 rdf:rest Nfc9340f605124b939736061d71b1467a
    152 N260b158288a34a01bd60909bd3fe691d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Liver Neoplasms
    154 rdf:type schema:DefinedTerm
    155 N26ec781f5c6045a2b72c666ba0a60795 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Colorectal Neoplasms
    157 rdf:type schema:DefinedTerm
    158 N287947dbe0964d1290dff675dbad5702 rdf:first sg:person.0771113555.48
    159 rdf:rest N5aae3737d1494562b9626f3e92352204
    160 N28f35eac6f3d401383545ecb98252d87 rdf:first sg:person.01044006441.91
    161 rdf:rest Nf9d1c2af848f4251a164c4bc64e23e4f
    162 N321649da373044f89ef7245fbaacd256 rdf:first sg:person.0620147214.05
    163 rdf:rest Na4f5f48c02434eb2a301289eb397a428
    164 N3361a6cd9c354432832be4fa86752068 schema:name Springer Nature - SN SciGraph project
    165 rdf:type schema:Organization
    166 N37bc006acc11401a82f093e4c2595b51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Organoplatinum Compounds
    168 rdf:type schema:DefinedTerm
    169 N474bc2bd6bd9409f918322e4acc1be11 schema:name doi
    170 schema:value 10.1186/1471-2407-12-356
    171 rdf:type schema:PropertyValue
    172 N483d23c304a24abb9b30eea3b890453a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Irinotecan
    174 rdf:type schema:DefinedTerm
    175 N49ed195f15a44c009e2e03b0d6497719 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Antineoplastic Combined Chemotherapy Protocols
    177 rdf:type schema:DefinedTerm
    178 N5aae3737d1494562b9626f3e92352204 rdf:first sg:person.01237306027.53
    179 rdf:rest N28f35eac6f3d401383545ecb98252d87
    180 N5c0656314ccb4e90a520f28b2e363372 rdf:first sg:person.0665375546.55
    181 rdf:rest rdf:nil
    182 N605e25359dae438496f939db88e81a9f rdf:first sg:person.01121153617.81
    183 rdf:rest N240d23d438c24bc789a00f547e475782
    184 N6d0d9c9783eb4517baec9c4e4471ba53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Antibodies, Monoclonal, Humanized
    186 rdf:type schema:DefinedTerm
    187 N82ee13284dd340d1b5419f82e955a049 schema:name dimensions_id
    188 schema:value pub.1032414305
    189 rdf:type schema:PropertyValue
    190 N835b9b3b5ce348a4b02180fdc3c301a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Combined Modality Therapy
    192 rdf:type schema:DefinedTerm
    193 N8976e451fbec4aae897a08ca1cf78b34 schema:volumeNumber 12
    194 rdf:type schema:PublicationVolume
    195 N92f48c3248e84d968f0d27085d478000 schema:issueNumber 1
    196 rdf:type schema:PublicationIssue
    197 Na4f5f48c02434eb2a301289eb397a428 rdf:first sg:person.015247652534.54
    198 rdf:rest N287947dbe0964d1290dff675dbad5702
    199 Nb072cafabd384940b5ce93632a49bc10 rdf:first sg:person.015465611257.98
    200 rdf:rest N321649da373044f89ef7245fbaacd256
    201 Nb549327fbd9f461cadce072ebafddf80 rdf:first sg:person.01270303133.74
    202 rdf:rest Nb072cafabd384940b5ce93632a49bc10
    203 Nc11b3c3ba76f420c886e2eeafe03fd41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    204 schema:name Fluorouracil
    205 rdf:type schema:DefinedTerm
    206 Nc2ba760a224b40349f2f9da6b8267b4c schema:name pubmed_id
    207 schema:value 22897915
    208 rdf:type schema:PropertyValue
    209 Ncdaa7f8034984bbf87bc47e12d3ffbfa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Camptothecin
    211 rdf:type schema:DefinedTerm
    212 Ncf33fb70b7eb4512a37089448c8c5a21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    213 schema:name Bevacizumab
    214 rdf:type schema:DefinedTerm
    215 Nf44d450238fd4479be67204294e98a54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    216 schema:name Multicenter Studies as Topic
    217 rdf:type schema:DefinedTerm
    218 Nf9d1c2af848f4251a164c4bc64e23e4f rdf:first sg:person.010361144542.53
    219 rdf:rest N5c0656314ccb4e90a520f28b2e363372
    220 Nfa76187e05054c4f9a182c26a44ab61c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    221 schema:name Randomized Controlled Trials as Topic
    222 rdf:type schema:DefinedTerm
    223 Nfc9340f605124b939736061d71b1467a rdf:first sg:person.0725537546.04
    224 rdf:rest Nb549327fbd9f461cadce072ebafddf80
    225 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    226 schema:name Medical and Health Sciences
    227 rdf:type schema:DefinedTerm
    228 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    229 schema:name Oncology and Carcinogenesis
    230 rdf:type schema:DefinedTerm
    231 sg:journal.1024632 schema:issn 1471-2407
    232 schema:name BMC Cancer
    233 schema:publisher Springer Nature
    234 rdf:type schema:Periodical
    235 sg:person.010361144542.53 schema:affiliation grid-institutes:grid.411941.8
    236 schema:familyName Schlitt
    237 schema:givenName Hans J
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010361144542.53
    239 rdf:type schema:Person
    240 sg:person.01044006441.91 schema:affiliation grid-institutes:grid.9018.0
    241 schema:familyName Richter
    242 schema:givenName Michael
    243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044006441.91
    244 rdf:type schema:Person
    245 sg:person.01121153617.81 schema:affiliation grid-institutes:grid.412315.0
    246 schema:familyName Stein
    247 schema:givenName Alexander
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121153617.81
    249 rdf:type schema:Person
    250 sg:person.01237306027.53 schema:affiliation grid-institutes:grid.411544.1
    251 schema:familyName Königsrainer
    252 schema:givenName Alfred
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237306027.53
    254 rdf:type schema:Person
    255 sg:person.01270303133.74 schema:affiliation grid-institutes:grid.412315.0
    256 schema:familyName Arnold
    257 schema:givenName Dirk
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270303133.74
    259 rdf:type schema:Person
    260 sg:person.01370366160.73 schema:affiliation grid-institutes:grid.411941.8
    261 schema:familyName Glockzin
    262 schema:givenName Gabriel
    263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370366160.73
    264 rdf:type schema:Person
    265 sg:person.015247652534.54 schema:affiliation grid-institutes:None
    266 schema:familyName Hollerbach
    267 schema:givenName Stephan
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015247652534.54
    269 rdf:type schema:Person
    270 sg:person.015465611257.98 schema:affiliation grid-institutes:None
    271 schema:familyName Edelmann
    272 schema:givenName Thomas
    273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015465611257.98
    274 rdf:type schema:Person
    275 sg:person.0620147214.05 schema:affiliation grid-institutes:grid.6363.0
    276 schema:familyName Hildebrandt
    277 schema:givenName Bert
    278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620147214.05
    279 rdf:type schema:Person
    280 sg:person.0665375546.55 schema:affiliation grid-institutes:grid.9018.0
    281 schema:familyName Schmoll
    282 schema:givenName Hans-Joachim
    283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665375546.55
    284 rdf:type schema:Person
    285 sg:person.0725537546.04 schema:affiliation grid-institutes:grid.9018.0
    286 schema:familyName Wienke
    287 schema:givenName Andreas
    288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725537546.04
    289 rdf:type schema:Person
    290 sg:person.0771113555.48 schema:affiliation grid-institutes:grid.5963.9
    291 schema:familyName Illerhaus
    292 schema:givenName Gerald
    293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771113555.48
    294 rdf:type schema:Person
    295 sg:pub.10.1007/bf00316981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038122014
    296 https://doi.org/10.1007/bf00316981
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1007/s00268-006-0140-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003334308
    299 https://doi.org/10.1007/s00268-006-0140-3
    300 rdf:type schema:CreativeWork
    301 sg:pub.10.1007/s00280-007-0588-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029987674
    302 https://doi.org/10.1007/s00280-007-0588-3
    303 rdf:type schema:CreativeWork
    304 sg:pub.10.1038/sj.bjc.6603011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024247066
    305 https://doi.org/10.1038/sj.bjc.6603011
    306 rdf:type schema:CreativeWork
    307 sg:pub.10.1038/sj.bjc.6605595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007402265
    308 https://doi.org/10.1038/sj.bjc.6605595
    309 rdf:type schema:CreativeWork
    310 sg:pub.10.1038/sj.bjc.6605940 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008545199
    311 https://doi.org/10.1038/sj.bjc.6605940
    312 rdf:type schema:CreativeWork
    313 sg:pub.10.1186/1471-2407-10-545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021313491
    314 https://doi.org/10.1186/1471-2407-10-545
    315 rdf:type schema:CreativeWork
    316 sg:pub.10.1186/1471-2407-10-567 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017854165
    317 https://doi.org/10.1186/1471-2407-10-567
    318 rdf:type schema:CreativeWork
    319 sg:pub.10.1245/aso.2006.05.039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035845557
    320 https://doi.org/10.1245/aso.2006.05.039
    321 rdf:type schema:CreativeWork
    322 grid-institutes:None schema:alternateName Department for Gastroenterology, Academic Teaching Hospital, Celle, Germany
    323 MedCenter Nordsachsen, Schkeuditz, Germany
    324 schema:name Department for Gastroenterology, Academic Teaching Hospital, Celle, Germany
    325 MedCenter Nordsachsen, Schkeuditz, Germany
    326 rdf:type schema:Organization
    327 grid-institutes:grid.411544.1 schema:alternateName Department of Surgery, University Hospital of Tübingen, Tübingen, Germany
    328 schema:name Department of Surgery, University Hospital of Tübingen, Tübingen, Germany
    329 rdf:type schema:Organization
    330 grid-institutes:grid.411941.8 schema:alternateName Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
    331 schema:name Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
    332 rdf:type schema:Organization
    333 grid-institutes:grid.412315.0 schema:alternateName University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    334 schema:name University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    335 rdf:type schema:Organization
    336 grid-institutes:grid.5963.9 schema:alternateName Department of Hematology/Oncology, Comprehensive Cancer Center University of Freiburg, Freiburg, Germany
    337 schema:name Department of Hematology/Oncology, Comprehensive Cancer Center University of Freiburg, Freiburg, Germany
    338 rdf:type schema:Organization
    339 grid-institutes:grid.6363.0 schema:alternateName Charité Centrum für Tumormedizin, Campus Virchow-Klinikum, Berlin, Germany
    340 schema:name Charité Centrum für Tumormedizin, Campus Virchow-Klinikum, Berlin, Germany
    341 rdf:type schema:Organization
    342 grid-institutes:grid.9018.0 schema:alternateName Department for Oncology/Hematology, Martin-Luther-University Halle, Ernst-Grube-Str. 40, 06120, Halle/Saale, Germany
    343 Koordinierungszentrum Klinische Studien Halle, Martin-Luther-University, Halle, Germany
    344 schema:name Department for Oncology/Hematology, Martin-Luther-University Halle, Ernst-Grube-Str. 40, 06120, Halle/Saale, Germany
    345 Koordinierungszentrum Klinische Studien Halle, Martin-Luther-University, Halle, Germany
    346 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...